TransMedics Group is trading at $80.08, down 4.04%, with no clear company-specific catalyst identified in available news. - The latest spotlight article covers an insider purchase from September 11, not a new catalyst. - The healthcare ETF was down 1.33% in the provided session context. - Broader-market weakness and a sharp rise in Treasury yields may add pressure, but available evidence does not establish a direct cause for the stock’s move.